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Summary Of 15 anti-CEA monoclonal antibodies, the first 8 were reactive only with CEA, while the
remaining 7 antibodies reacted with epitopes commonly expressed on CEA and the normal cross-reacting
antigen, NCA. Separate and distinct, conformation-dependent (i.e. susceptible to reduction and alkylation),
CEA-associated epitopes were identified using antibodies 1, 2 and 3. Antibodies 4 to 7 defined a series of
conformation-independent epitopes which were topographically closely related on the CEA molecule.
Antibody number 8 reacted with a separate determinant found on CEA but not NCA, and this also was
resistant to reduction and alkylation.
Antibody number 9 defined an epitope which was commonly expressed on CEA and NCA. This epitope
was conformation-dependent and was the most sensitive to NaIO4. The remaining antibodies, 10 to 15, which
also reacted with CEA and NCA, defined an immunodominant region of these molecules since the 6 epitopes
were clearly closely related, but not necessarily identical.
The findings presented establish a rational basis for the selection of combinations of anti-CEA antibodies
for diagnostic and therapeutic purposes.
Carcinoembryonic antigen (CEA) is a carbohydrate-rich
glycoprotein, often expressed in tumours of the human
gastro-intestinal tract, and which consists of a single poly-
peptide chain with about 40 N-linked oligosaccharide chains
(Rogers, 1983; Chandrasekaran et al., 1983). Purified CEA
preparations exhibit microheterogeneity which has been
attributed to variations in its associated oligosaccharides
(Coligan et al., 1973; Primus et al., 1983) and frequently
inimunochemical procedures have been employed to define
the structure of CEA. Monoclonal antibodies have proved to
be particularly valuable in this respect and epitopes
specifically expressed on CEA molecules have been clearly
distinguished from other epitopes commonly found on CEA
molecules and immunologically-related glycoproteins
associated with certain normal tissues (Kuroki et al., 1984;
Blaszczyk et al., 1984; Haggarty et al., 1986).
In the present investigation, a panel of 15 anti-CEA
monoclonal antibodies have been used to probe the epitope
structure of CEA molecules and to establish a basis for the
selection of reagents for antibody directed targeting to
tumours of both radioisotopes for immunoscintigraphy and
cytotoxic drugs for therapy.
Materials and methods
Monoclonal antibodies
Monoclonal antibodies 1 to 15 were prepared by
conventional hybridoma technology by which the spleen cells
from immunized BALB/c mice were fused with cells of the
mouse myeloma, P3NS1 (Kohler & Milstein, 1975). Mice
were immunized with purified CEA, colorectal tumour sub-
cellular membranes or viable colonic tumour cells and
antibodies were selected for their reactivity with CEA (Price
et al., 1985; Durrant et al., 1986). All antibodies were the
products of separate fusions with the exception of antibodies
6 and 7, and antibodies 12 and 13. The immunoglobulin
class and subclass of antibodies was determined as
previously described (Price & Baldwin, 1984). Monoclonal
antibodies were purified from ascitic fluids or from
hybridoma tissue culture supernatants by their binding to
and elution from Sepharose-protein A (Pharmacia, Uppsala,
Sweden).
Antigen preparations
CEA was purified from hepatic metastases from primary
colonic adenocarcinoma according to the method of Krupey
et al., (1972) and NCA was isolated from human spleen as
previously described (Blaszczyk et al., 1984; Price et al., 1985).
The purity of both antigen preparations was examined by
sodium dodecyl sulphate polyacrylamide gel electrophoresis.
CEA gave a single diffuse band migrating with an apparent
molecular weight of 180kD while NCA preparations
showed a single band at 60kD.
Chemical treatment of CEA
CEA was reduced and alkylated with iodoacetamide
according to Krantz and Laferte (1983). CEA (0.25mgml-1)
was dissolved in 0.7 M Tris-HCl, pH 8.8, containing 0.2%
SDS. After flushing the vial with nitrogen, 15 mM dithio-
threitol was added, and it was sealed and heated at 100°C
for 5min. After cooling to room temperature, 50 mm iodo-
acetamide was added and the reaction mixture was kept in
the dark for 30min. Reagents were then removed by passage
through a column of Sephadex G25 (Pharmacia, Uppsala,
Sweden) equilibrated with PBS, pH 7.3. CEA preparations
were also treated with NalO4 solutions (Westwood &
Thomas, 1975). CEA was dried onto the surface of wells of
Terasaki microtest plates (well capacity - 10pl) as described
in the following section. Adsorbed CEA was then treated
with 0.005 M NaIO4 for 20h at room temperature in the
dark. Reagents were removed by washing the microtest
plates with PBS.
Radioisotopic antiglobulin test
Antigen preparations (50 pgml- in PBS +0.02% NaN3)
were added to 60-well Terasaki microtest plates (well capacity
- 10pl; Labtech Division, Miles Laboratories, Naperville, IL,
USA) at 10 p1 per well. Plates containing CEA or NCA were
air dried by overnight incubation at 37°C. The wells were
washed 4 times with a washing buffer consisting of
PBS +0.1% bovine serum albumin (BSA) +0.1% rabbit
serum (RbS)+0.02% NaN3. During the final wash cycle, the
wells were incubated with the washing buffer for at least
30min to complete the blocking of non-specific binding
adsorption sites. Hybridoma supernatants or purified
monoclonal antibodies (at the saturating concentration of
1 pgml 1 in washing buffer), or washing buffer alone in
negative controls, were added at 10pl per well. After
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incubation for 1 to 2h at room temperature, the wells were
aspirated and washed 4 times. '251-labelled, affinity purified
F(ab')2 fragments of rabbit anti-mouse Ig were added at
-105cpmlOpl-l per well (radioiodination of this reagent
was performed using the chloramine T procedure of
Jensenius and Williams (1974) using 500 jiCi 1251 per 25 jug
protein). Incubation was continued for 1 to 2 h at room
temperature. The wells were aspirated, then washed 6 times,
after which the radioactivity in each well was determined.
The non-specific binding of antibodies to 'PBS-coated' and
'BSA/RbS-blocked' wells was determined and the values
obtained were subtracted from those determined with
antigen-coated, BSA/RbS-blocked and antibody treated
wells.
Competitive inhibition of 125I-labelled antibody binding
Monoclonal antibodies were radiolabelled using the
chloramine T procedure (Jensenius & Williams, 1974) with
500yCi 1251 per 25pg protein. Labelled antibodies (5 jl
aliquots) were admixed with unlabelled antibodies (purified
antibodies or tissue culture supernatants - 5 jl aliquots) in
CEA-coated wells of Terasaki microtest plates, and the
concentration of the labelled antibody was fixed at
-I0 cpm 10 l-1 per well. After incubation for I to 2h at
room temperature, the wells were aspirated, washed 6 times
and the radioactivity remaining in each well was determined.
Results
Monoclonal antibody reactivity with CEA, NCA and
chemically treated CEA
As shown in Table I, of the 15 anti-CEA antibodies
examined, 14 belonged to the IgG immunoglobulin class,
while the remaining one, number 8, was an IgM antibody.
The IgG antibodies were either of the IgGI or IgG2a isotype
(Table I).
All antibodies were strongly reactive with CEA in the
radioisotopic antiglobulin assay (Table I). Antibodies 1 to 8
failed to react with the normal cross-reacting antigen, NCA,
whereas antibodies 9 to 16 bound to NCA. Within this latter
group, antibody 15, and to a lesser extent, antibody 14 were
preferentially reactive with CEA and antibody 9 appeared
more reactive with NCA.
Further subgrouping of the epitopes defined by these
antibodies was achieved by examining the retention of their
Table I Monoclonal antibody reactivity with
activity to heat- and chemically-treated CEA
capacity to bind to CEA after antigen modification using
various treatments. As shown in Table I, the epitopes for
each of the 15 antibodies were largely resistant to the effects
of heat treatment at 100°C for 5min, indicative of their
overall stability. However, when CEA was reduced and
alkylated, it was clear that 4 of the antibodies no longer
bound to the antigen (i.e. antibodies numbered 1, 2, 3 and 9
- Table I) while the binding of the remaining antibodies to
modified antigen was unaffected. The epitopes defined by the
first three CEA-reactive antibodies (1, 2 and 3) and the
NCA-reactive antibody number 9, thus require the retention
of conformation for full expression of their antibody binding
activity. The susceptibility of the various epitopes to
modification with 0.005 M NaIO4 revealed less marked
differences between these antibodies. The epitope of
antibody number 3 was evidently the most resistant to
NaIO4 treatment while that defined by the antibody number
9 was extremely susceptible to inactivation. While antibodies
13 and 15 were not examined in this particular assay, it was
determined that their capacity to react with periodate-treated
CEA (treated in solution, rather than adsorbed to plastic)
was similar to that of antibodies 10, 11, 12 and 14.
Discrimination between the various epitopes in their capacity
to bind their respective antibodies, was progressively lost in
samples exposed to increasing concentrations of periodate,
this being indicative of increasing modification of the protein
core as well as alteration to carbohydrate moieties.
Competitive inhibition of12I5-labelled antibody to CEA
The 15 monoclonal antibodies were tested for their capacity
to inhibit the binding of radiolabelled antibodies to CEA.
Unlabelled antibodies as inhibitors were tested as purified
antibodies (at concentrations of 1, 3 and 10igml-1) and/or
as hybridoma supernatants (at dilutions of neat, 1/3 and
1/10). An example of the data obtained is illustrated in
Figure 1. The level of binding of each radiolabelled antibody
to CEA in the absence of an inhibitor was set at 100% and
the binding of labelled antibody in the presence of the
inhibitor was related to this figure. Some antibodies were
only available as purified preparations (e.g. antibody 2 in
Figure 1) while with others, such as antibody 1, only small
quantities of hybridoma supernatant were available.
Nevertheless, when purified antibodies and supernatants
were assayed as inhibitors in parallel tests (e.g. using
antibodies 3 to 6 in Figure 1), their inhibitory capacities
CEA and NCA, and retention of binding
Percentage retention of
antibody binding activity
after treatment ofCEA with:
Immuno- Mean cpm±s.d.
Mono- globulin bound to: Heat Reduction
clonal classl 100°C & alkyl- 0.005 m
antibody subclass CEA NCA 5min ation NaIO4
1 IgG2a 3,937+ 403 -51+ 24 100+ 3 2+ 1 22+2
2 IgGI 6,132+ 202 65+ 87 95+ 4 4+ 2 28+2
3 IgG2a 7,341 + 494 16+ 21 99+ 1 1 + 0 68+8
4 IgG2a 7,488 + 125 123 + 44 88+ 3 93 + 4 9+1
5 IgGI 8,173+ 220 -66+ 61 102+ 7 76+ 1 9+1
6 IgGI 9,216±1,016 111± 25 86+ 3 83+ 6 20+1
7 IgGI 8,220+ 646 -33+ 3 92+ 2 95+10 25+8
8 IgM 3,099+ 174 -6+ 25 93+ 5 99+ 5 21+3
9 IgGI 4,618± 236 6,983 + 108 98 + 3 9+ 1 2+1
10 IgGI 8,532± 588 7,174+323 87+ 4 97+ 5 48+2
11 IgGI 7,140± 356 5,081 + 135 89+ 3 91+10 42+2
12 IgGI 6,227± 302 5,972+122 86+ 3 78+12 50+6
13 IgGI 6,520+ 535 4,075+274 98± 14 73+ 3 NTa
14 IgG2a 6,698 ± 111 2,876+300 101 + 5 77+ 6 27 +3
15 IgGI 7,987± 130 1,319+197 86+ 7 68+ 1 NT
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were essentially equivalent at the concentrations and
dilutions selected. This is in accord with the general
experience that antibody concentrations in the supernatants
of these anti-CEA hybridomas have been found to be in the
region of 10 to 15ygml-1. The results of these competition
reactions were summarized as shown in Table II. A '+ + +'
inhibitory reaction was defined as that obtained when more
than 50% inhibition was achieved with the competing
antibody at less than jigml or with supernatant diluted
more than 1/10. A '-' reaction was one in which 50%
inhibition of labelled antibody binding was not achieved at
any concentration or dilution tested. Intermediate inhibitions
of '+ +' and '+' relate to whether 50% inhibition was
obtained within the inhibitor concentration ranges of 1 to 3,
or 3 to 10 gm -1, respectively (or supernatant dilution
ranges of 1/10 to 1/3, or 1/3 to neat, respectively). The
inhibitory capacities of purified antibodies and supernatants
were usually equivalent using these definitions but when
differences were recorded, the higher category of inhibition
was included in Table II.
It can be seen from the results summarized in Table II
that maximum inhibitions C+ + +') were obtained with
homologous combinations of inhibitor and labelled antibody
(with the exception of antibody 10). Certain antibodies were
very restrictive in their inhibitory reactivities (e.g. antibodies
1, 2 and 3) indicating that their respective epitopes were
sufficiently separated to permit the binding of both inhibitor
and labelled antibody without interference with each other.
Other antibodies such as the specific anti-CEA antibody
number 6 and the NCA/CEA reactive antibody number 14
displayed a broader spectrum of inhibitory reactivities
indicative of a closer topographical grouping of the epitopes
involved. Apparent inconsistencies were obtained with
certain combinations- 'cold' antibody 6 inhibited labelled
antibody 4 binding but 'cold' antibody 4 failed to inhibit
IonIof (,' .d .m
Concentration of competing ('cold') antibody (,ug mI-,; *_s )
10 1 10 1 103 1 1 10 1 31 10 1 103 1 103 1
Reciprocal of competing hybridoma supernatant (_--)
Figure 1 Competitive inhibition of binding of 125I-labelled anti-
CEA antibodies to CEA. Unlabelled antibodies I to 6 were
tested as 'cold' antibody inhibitors using purified antibody
preparations (- 0) or hybridoma supernatants (-*).
labelled antibody 6 binding to CEA. This type of finding is
considered to reflect differences in the affinity of pairs of
antibodies for their respective epitopes although the
information obtained with antibodies 4 and 6 for example, is
sufficient to deduce that their epitopes are close enough for
steric interactions between their antibodies to be possible,
even though they are only demonstrable in one of the
combinations.
Figure 2 is a diagrammatic representation of the
inhibitory reactions described in Table II. Initially, for the
preparation of this figure, each antibody-defined epitope was
described by a circle. Antibodies showing reactivity only with
CEA, and those cross-reactive with NCA and CEA (Table I)
are indicated by the stippled and open circles respectively.
Overlapping between pairs of circles was drawn to indicate
an inhibitory interaction between the respective antibodies.
Discussion
As shown in Figure 2, antibodies 1 and 2 react with distinct,
conformation-dependent epitopes on the CEA molecule;
similarly, antibody 3 reacts with a CEA-associated,
conformation-dependent (and relatively periodate-resistant-
Table I) epitope, but from the 'cold' antibody inhibition tests
in Figure 1 and Table II, the epitope of antibody 3 is closer
to the main group of epitopes than is antibody 1 or 2. The
antibodies 4 to 7 define conformation-independent (i.e. a
resistance to reduction and alkylation - Table I) CEA-
specific epitopes which appear to be topographically close to
each other - there are several cross-inhibitory interactions
between these antibodies so that it is probable that they
react with an immunodominant area of the CEA molecule.
Antibody number 8, the only IgM antibody (Table I),
defines an epitope which is unrelated to those reactive with
the other CEA-binding antibodies, 1 to 7.
Of the antibodies which were reactive with both CEA and
NCA, antibody number 9 was unique - its epitope was
conformation-dependent and very sensitive to periodate
(Table I). Unlabelled antibody 9 failed to inhibit the binding
of all of the labelled antibodies tested with the exception of
antibodies 3 and 4, although these inhibitory reactions were
very weak (Table II). The remaining antibodies 10 to 15
were all resistant to reduction and alkylation, and in each
combination of labelled antibody and inhibitor tested, all
antibodies in this group were cross-inhibitory (Table II).
Thus, these antibodies appear to belong to a group which
react with an immunodominant area of the CEA molecule
which is shared between CEA and NCA. Each of these
considerations have been taken into account in developing
the model in Figure 2.
The number of epitopes on the CEA molecule would
appear to be limited. A maximum number of 10 CEA-
specific epitopes was identified using polyclonal antisera
(Sundblad et al., 1976). More recently, using a panel of 18
monoclonal antibodies, 12 different epitopes were
distinguished, including 7 which were CEA-specific
(Haggarty et al., 1986). In similar investigations, Kuroki et
al. (1984) defined 8 epitopes using a panel of 11 monoclonal
antibodies, and Harwood et al. (1986) identified at least 6
unrelated epitopes using 15 monoclonal antibodies. In the
present study, there were 7 distinct epitopes, including the 2
epitope domains defined by antibodies 4 and 7 and 10 to 15
which are likely to represent immunodominant areas of the
CEA molecule. Of these 7, two were commonly expressed on
CEA and NCA (Table I, Figure 2).
The present findings provide a rational basis for selecting
anti-CEA antibodies of appropriate specificity as well as
antibody class or subclass for a number of potential clinical
applications. These include their use in immunodiagnostic
tests for circulating CEA and for the localization of tumours
in patients using radiolabelled antibodies (Begent, 1985;
Mach et al., 1981). Such antibodies may be further employed
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Table II 'Cold antibody inhibition of CEA binding of radiolabelled anti-CEA monoclonal
antibodies
'Cold' antibody inhibition ofCEA binding
ofradiolabelled antibody
Competing
antibody 2 3 4 5 6 10 11 15
1 - - - _ _ _ _
2 +++ - -
3 - ++ - - _
4 - - + _
5 - + ++ +++ + - _ _
6 - - +++ + +++ ++ + _
7 - - ++ ++ + _ _ _
8 - - - _ _ + + _
9 - + + _ _ _ _
10 - - - + ++ ++ ++
11 - - - - + + + + ++ +++ +++
12 - + - - + + + + + NTa + + +
13 - + - + + + + + NT + +
14 - + + + + + + NT + +
15 - - - - ++ ++ NT ++
'NT - Not tested.
2ewe 15at-E ooloa niois I ae hr w
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reactive with both CEA and NCA.
as vehicles to target cytotoxic drugs or toxins to tumour
deposits and the results described assist in the formulation of
'cocktails' of anti-CEA antibodies which would be additive
rather than inhibitory in their binding to CEA.
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